Significant reduction in the incidence of non-coronavirus infections in patients with chronic lymphocytic leukemia on ibrutinib and venetoclax treatment during the COVID-19 pandemic: An additional benefit of lockdown.

Kislova, Maria; Petrenko, Andrei; Dmitrieva, Elena A; Milenkin, Alexander; Nikitin, Konstantin E; Ptushkin, Vadim V; Shabunin, Alexey V; Nikitin, Eugene A

Kislova, Maria; Petrenko, Andrei; Dmitrieva, Elena A; Milenkin, Alexander; Nikitin, Konstantin E; Ptushkin, Vadim V; Shabunin, Alexey V; Nikitin, Eugene A.

Afiliación

Kislova M; Botkin Hospital, Moscow, Russia.
Petrenko A; Botkin Hospital, Moscow, Russia.
Dmitrieva EA; Russian Medical Academy of Continuous Medical Education, Moscow, Russia.
Milenkin A; Botkin Hospital, Moscow, Russia.
Nikitin KE; Moscow Institute of Physics and Technology, Moscow, Russia.
Ptushkin VV; Moscow Institute of Physics and Technology, Moscow, Russia.
Shabunin AV; Botkin Hospital, Moscow, Russia.
Nikitin EA; Russian Medical Academy of Continuous Medical Education, Moscow, Russia.

Hematol Oncol ; 41(4): 683-693, 2023 Oct.

Article en En | MEDLINE | ID: mdl-37058711

Palabras clave

chronic lymphocytic leukemia; ibrutinib; infections; lockdown; out-patient health care visits; pandemic

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hematol Oncol Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google